All News

Lupusfoto.jpg

Phase 3 Trials of Baricitinib Disappoint in SLE

Jack Cush, MD

Despite the encouraging phase II trial results of baricitinib in systemic lupus erythematosus (SLE) patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE, thereby halting development of baricitinib in SLE. 

Read Article
cost.price_.biologic.injectable.jpg

New Drug Formulations – For Patients or Profits?

Madelaine Feldman, MD

Wang et al., in a JAMA Network Research Letter, recently reviewed Medicaid expenditures on adalimumab (ADA), sold under the brand name HUMIRA®. They noted that the introduction of the citrate-free formulation cost an extra $4.4B to Medicaid between 2014 and 2021.

Read Article
RheumNow Podcast square

Half the Experts are Wrong (2.17.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.

Read Article
computer screen safety

Drug Safety Differences with New Novel Therapies in RA

Jack Cush, MD

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Read Article
Cutaneous.lupus.SLE.Face.dermnetnz

Deucravacitinib - Effective in Systemic Lupus Erythematosus

Jack Cush, MD

A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in  adults with active systemic lupus erythematosus (SLE).

Read Article
Achilles,ankle,heel

GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

Jack Cush, MD

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article
Achilles,ankle,heel

ICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

Jack Cush, MD

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article
ChatGPT,computer,learning

ChatGPT - A Boon or Threat to Scientific Publication?

Jack Cush, MD

ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more.

Read Article
RheumNow Podcast square

Burnout #10 (2.3.2023)

Jack Cush, MD

Dr. Jack Cush reviews the past week of news on RheumNow.com.

Read Article
5 Nordic register study of new b/tsDMARD starts in in PsA - 5659 ADA (56% biologic-naïve) & 4767 other b/tsDMARD (21% naïve) starts. ADA more often 1st line; newer b/tsDMARDsin biologic-experienced. 2nd line retention: ADA 65%, ABA 45%, Otez 43%. https://t.co/XKLiana6vB https://t.co/PotwYlYXto

Links:

Dr. John Cush RheumNow ( View Tweet)
Survey of 300 Rheums, GI, Derms - concerns w/ new biosimilars - majority say economics arent favorable to switch to biosimilar - Yet majority "very to somewhat” comfortable w/ biosimilars - US: Slow biosimilar uptake due to disappointing costs https://t.co/DOhrfELssY https://t.co/f2iy9igq5d

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/ b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−) RTX 9% (p .03) ABA 6% JAKi 1% IL‐6i 0% TNFi 0% Safe to use TNFi, JAKi, IL6 mAbs https://t.co/U76or69bnB https://t.co/5QbR3WqzUG

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 ⁦@RheumNow⁩ ⁦@RWCSmtg⁩ https://t.co/qMGA6IdtUE
Dr. Rachel Tate uptoTate ( View Tweet)
ADA biosimilars: one is out now and seven due out by July. “It’s time to get onboard with biosimilars” @RheumNow @RWCSmtg #RWCS23

Dr. Rachel Tate uptoTate ( View Tweet)

NOVESA trial ziritaxestat (an autotaxin inhibitor) in 33 early diffuse systemic sclerosis pts. After 24 wks, ziritaxestat showed signif reduction in mRSS (–8.9 vs. –6.0 PBO; P=0.04). It was well tolerated & showed biologic effect w/ reduced LPA C18:2 https://t.co/GKC2TKOQhE https://t.co/AUaminOyiH

Links:

Dr. John Cush RheumNow ( View Tweet)
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://t.co/KTYn1kv3qO https://t.co/eWbvMSBLxm

Links:

Dr. John Cush RheumNow ( View Tweet)
211 Adult Crohn's pts w/ steroid-free remission >6mo on Combo infliximab & immunosuppressant either cont combo or W/D IFX or Immsup. 2-yr relapse rates: 14% Combo vs, 36% IFX vs 10% Immunosup. WD of IFX had 3.45-4.76 fold incr rsk of flare https://t.co/6EbM3Vx0Ei https://t.co/5ZOE2oxCl0

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment failures studied in 718 RA pts - csDMARDs D/Cs intolerance (22%), inefficacy (20%), acute Rxns (5%), severe infx(0.6%) - bDMARDs D/Cs inefficacy (29%), intolerance (10%), acute Rxns (6%), severe infx (1.5%) - Multi-drug ifailure 5.7-8.4% https://t.co/FdoP77uELe https://t.co/dQjTNncABc

Links:

Dr. John Cush RheumNow ( View Tweet)
Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/8R51VLUbvX https://t.co/vc3JJKXfk3

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved the 1st BTK (Bruton’s tyrosine kinase) inhibitor (Jaypirca™ or pirtobrutinib) for adults with refractory mantle cell lymphoma. BTK inhibitors are also being developed for use in MS, RA, SLE, pemphigus & more https://t.co/599tK21H1Z https://t.co/KSqMMDWmfd

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×